BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nayer A, Asif A. Atypical hemolytic-uremic syndrome: a clinical review. Am J Ther. 2016;23:e151-e158. [PMID: 24681522 DOI: 10.1097/mjt.0b013e31829b59dc] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Asif A, Nayer A, Haas CS. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab. J Nephrol 2017;30:347-62. [PMID: 27848226 DOI: 10.1007/s40620-016-0357-7] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 7.2] [Reference Citation Analysis]
2 Almalki AH, Sadagah LF, Qureshi M, Maghrabi H, Algain A, Alsaeed A. Atypical hemolytic-uremic syndrome due to complement factor I mutation. World J Nephrol 2017; 6(6): 243-250 [PMID: 29226095 DOI: 10.5527/wjn.v6.i6.243] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Cao M, Ferreiro T, Leite BN, Pita F, Bolaños L, Valdés F, Alonso A, Vázquez E, Mosquera J, Trigás M, Rodríguez S. Two cases of atypical hemolytic uremic syndrome (aHUS) and eosinophilic granulomatosis with polyangiitis (EGPA): a possible relationship. CEN Case Rep 2017;6:91-7. [PMID: 28509134 DOI: 10.1007/s13730-017-0251-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
4 Dejman A, Alavi SN, Thomas DB, Stefanovic A, Asif A, Nayer A. The potential role of complements in cocaine-induced thrombotic microangiopathy. Clin Kidney J 2018;11:26-8. [PMID: 29423197 DOI: 10.1093/ckj/sfx061] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
5 Nayer A, Ortega LM. Catastrophic antiphospholipid syndrome: a clinical review. J Nephropathol 2014;3:9-17. [PMID: 24644537 DOI: 10.12860/jnp.2014.03] [Cited by in F6Publishing: 24] [Reference Citation Analysis]
6 Alonso Valente R, García Rodríguez GE, García Marcote Y, Fidalgo Díaz M, Becerra Mosquera V, Novoa García D, Cordal Martínez T, Díaz Rodríguez C. Discontinuation of Peritoneal Dialysis after Late Initiation of Eculizumab in a Case of Familial Atypical Hemolytic-Uremic Syndrome: A Case Report. Case Rep Nephrol Dial 2017;7:18-25. [PMID: 28612003 DOI: 10.1159/000457950] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
7 Bajwa R, DePalma JA, Khan T, Cheema A, Kalathil SA, Hossain MA, Haroon A, Madhurima A, Zheng M, Nayer A, Asif A. C3 Glomerulopathy and Atypical Hemolytic Uremic Syndrome: Two Important Manifestations of Complement System Dysfunction. Case Rep Nephrol Dial 2018;8:25-34. [PMID: 29594148 DOI: 10.1159/000486848] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Zuckerman R, Asif A, Costanzo EJ, Vachharajani T. Complement activation in atypical hemolytic uremic syndrome and scleroderma renal crisis: a critical analysis of pathophysiology. J Bras Nefrol 2018;40:77-81. [PMID: 29796581 DOI: 10.1590/2175-8239-JBN-3807] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Pugh D, O'Sullivan ED, Duthie FA, Masson P, Kavanagh D. Interventions for atypical haemolytic uraemic syndrome. Cochrane Database Syst Rev 2021;3:CD012862. [PMID: 33783815 DOI: 10.1002/14651858.CD012862.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]